BioTuesdays
180-Life-Sciences
Markets

Maxim starts 180 Life Sciences at buy; PT $11

Maxim Group initiated coverage of 180 Life Sciences (NASDAQ:ATNF) with a “buy” rating and $11 price target. The stock closed at $5.67 on Sept. 14. 180 Life Sciences is developing anti-inflammatory products with three...

September 15, 2021
Aadi-Bioscience
Markets

Ladenburg starts Aadi Bioscience at buy; PT $51

Ladenburg Thalmann launched coverage of Aadi Bioscience (NASDAQ:AADI) with a “buy” rating and price target of $51. The stock closed at $27.96 on Sept. 13. Aadi is a clinical-stage biotechnology company with a single...

September 14, 2021
Assembly Biosciences
Markets

HCW starts Assembly Biosciences at neutral; PT $3.50

H.C.Wainwright initiated coverage of Assembly Biosciences (NASDAQ:ASMB) with a “neutral” rating and price target of $3.50. The stock closed at $3.23 on Sept. 10. Assembly is focused on developing treatments for chronic...

September 13, 2021
Effector-Therapeutics
Markets

Cantor starts eFFECTOR Therapeutics at OW; PT $50

Cantor Fitzgerald launched coverage of eFFECTOR Therapeutics (NASDAQ:EFTR) with an “overweight” rating and price target of $50. The stock closed at $26.59 on Sept. 10. eFFECTOR is focused on developing a new class of...

September 13, 2021
ContraFect Logo
Markets

SVB Leerink starts ContraFect at OP; PT $14

SVB Leerink initiated coverage of ContraFect (NASDAQ:CFRX) with an “outperform” rating and sum-of-the-parts price target of $14. The stock closed at $3.90 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that...

September 9, 2021
Aligos-Therapeutics
Markets

SVB Leerink starts Aligos Therapeutics at OP; PT $29

SVB Leerink initiated coverage of Aligos Therapeutics (NASDAQ:ALGS) with an “outperform” rating and $29 price target. The stock closed at $15.31 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that Aligos is unique among...

September 9, 2021
scPharmaceuticals
Markets

SVB Leerink starts scPharmaceuticals at MP; PT $6

SVB Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with a “market perform” rating sum-of-the-parts PT of $6. The stock closed at $5.95 on Sept. 8. Analyst Roanna Ruiz, Ph.D., writes that, among other...

September 9, 2021
Greenlane
Markets

AGP starts Greenlane at buy; PT $6

Alliance Global Partners initiated coverage of Greenlane Holdings (NASDAQ:GNLN) with a “buy” rating and $6 price target. The stock closed at $2.73 on Sept. 3. Analyst Aaron Grey writes that Greenlane is now positioned...

September 7, 2021
Eliem-Therapeutics
Markets

Stifel starts Eliem Therapeutics at buy; PT $35

Stifel launched coverage of Eliem Therapeutics (NASDAQ:ELYM) with a “buy” rating and price target of $35. The stock closed at $27.56 on Sept. 3. Eliem is a clinical-stage biotechnology company focused on developing...

September 7, 2021
Surrozen
Markets

Stifel starts Surrozen at buy; PT $19

Stifel launched coverage of Surrozen (NASDAQ:SRZN) with a “buy” rating and $19 target price. The stock closed at $7.24 on Sept. 3. Surrozen discovers and develops biologic drug candidates to selectively modulate the Wnt...

September 7, 2021
Assembly Biosciences
Markets

WB cuts Assembly Biosciences to MP from OP

William Blair downgraded Assembly Biosciences (NASDAQ:ASMB) to “market perform” from “outperform” after the company discontinued clinical development of ABI-H2158, its second-generation core inhibitor for the treatment...

September 2, 2021
Talis-Logo
Markets

BTIG cuts Talis Biomedical to neutral without PT

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...

September 1, 2021
Palisade Bio Logo
Markets

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...

August 31, 2021
Tryp_Therapeutics
Markets

Ladenburg starts Tryp Therapeutics at buy; PT $2

Ladenburg Thalmann initiated coverage of Tryp Therapeutics (OTCQB:TRYPF; CSE:TRYP) with a “buy” rating and $2 price target. The stock closed at 37 cents on Aug. 25. Tryp is focused on developing psychedelic...

August 26, 2021
Rani-Therapeutics
Markets

Analysts start Rani Therapeutics at buy; PT $24

Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...

August 25, 2021
RxSight
Markets

Analysts start RxSight at buy

Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...

August 24, 2021
Icosavax
Markets

WB starts Icosavax at outperform

William Blair launched coverage of Icosavax (NASDAQ:ICVX) with an “outperform” rating. The stock closed at $34.09 on Aug. 20. “We believe Icosavax stands to benefit from both the medical and investment communities’...

August 23, 2021
Markets

HCW starts IVERIC Bio at buy; PT $20

H.C. Wainwright launched coverage of IVERIC Bio (NASDAQ:ISEE) with a “buy” rating and price target of $20. The stock closed at $9.07 on Aug. 18. Analyst Matthew Caufield writes that IVERIC’s retinal platform...

August 19, 2021
IMAC-Logo
Markets

AGP cuts IMAC to neutral; PT to $1.75 from $2.35

Alliance Global Partners downgraded IMAC Holdings (NASDAQ:IMAC) to “neutral” and reduced its price target to $1.75 from $2.35 after the Center for Medicare and Medicaid Services (CMS) requested repayment of $2.9-million...

August 19, 2021
Amryt-Logo
Markets

SVB Leerink starts Amryt Pharma at OP: PT $22

SVB Leerink initiated coverage of Amryt Pharma PLC (NASDAQ:AMYT) with an “outperform” rating and price target of $22. Analyst Mani Foroohar, M.D., writes that Amryt’s model of acquiring niche commercial or near...

August 19, 2021
Portage Biotech Logo
Markets

Cantor starts Portage Biotech at OW; PT $35

Cantor Fitzgerald launched coverage of Portage Biotech (NASDAQ:PRTG) with an “overweight” rating and $35 price target. The stock closed at $18.95 on Aug. 18.  Portage Biotech is a clinical biopharmaceutical company...

August 19, 2021